{
    "clinical_study": {
        "@rank": "16751", 
        "arm_group": [
            {
                "arm_group_label": "KHK4827 140mg SC", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KHK4827 210mg SC", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827\n      in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have\n      completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or\n      psoriatic erythroderma who have completed the Study 4827-004 (Study 004)."
        }, 
        "brief_title": "A Phase 3 Clinical Study of KHK 4827", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Psoriasis Vulgaris,", 
            "Psoriatic Arthritis,", 
            "Pustular Psoriasis,", 
            "Psoriatic Erythroderma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Dermatitis, Exfoliative", 
                "Psoriasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has voluntarily signed the written informed consent form to participate in\n             this study\n\n          -  Subject has completed the week 52 evaluation either in Study 003 or 004\n\n        Exclusion Criteria:\n\n          -  Subject has had a serious infection, defined as requiring systemic treatment with\n             antibiotics or antivirals (excluding oral administration)\n\n          -  Subject has been judged to be ineligible for participation in the study by the\n             investigators/sub investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052609", 
            "org_study_id": "4827-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "KHK4827 140mg SC", 
                "description": "Experimental1:KHK4827 140mg subcutaneous injection", 
                "intervention_name": "KHK4827 140mg SC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "KHK4827 210mg SC", 
                "description": "Experimental2:KHK4827 210mg subcutaneous injection", 
                "intervention_name": "KHK4827 210mg SC", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chiyoda-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "100-8185"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and types of adverse events and adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Anti-KHK4827 antibody", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in psoriasis area and severity index (PASI) compared to the data obtained before the first dose of investigational product in this study.", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Percent improvement in PASI", 
                "safety_issue": "Yes", 
                "time_frame": "28 Weeks"
            }, 
            {
                "measure": "PASI 50, 75, 90, and 100", 
                "safety_issue": "Yes", 
                "time_frame": "28 Weeks"
            }, 
            {
                "measure": "Static physician's global assessment (sPGA) of \"0 (clear) or 1(almost clear)\"", 
                "safety_issue": "Yes", 
                "time_frame": "28 Weeks"
            }, 
            {
                "measure": "sPGA of \"0 (clear)", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Change in body surface area involvement (BSA) of lesion", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Clinical Global Impression (CGI)", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "American College of Rheumatology (ACR) 20", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Pustular symptom score", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Serum KHK4827 concentration", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}